According to filings with the U.S. Securities and Exchange Commission, Alpenglow Biosciences is raising up to $4,850,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Nicholas Reder played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Alpenglow Biosciences
Founded in 2018, Seattle-based Alpenglow Biosciences is a privately held, early-stage life sciences company focused on accelerating drug development and improving clinical diagnostics with AI-enabled, 3D imaging technology. Our platform solution provides new spatial biology insights with greater accuracy by digitizing entire tissues while keeping samples intact for additional analysis. Alpenglow partners with pharmaceutical companies to develop better therapeutics and greater understanding of biodistribution, mechanism of action, and rank ordering of potential candidates using our patented technology. Five of the top 10 pharma companies work with Alpenglow to accelerate development timelines, gain new insights, and improve therapeutic success. We are hiring talented individuals for roles in business development, wet lab, hardware, and software.

To learn more about Alpenglow Biosciences, visit http://www.alpenglowbiosciences.com/

Contact:
Nicholas Reder, Chief Executive Officer
206-659-7920

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.